Over the last decade, the FDA has approved five new medications for the treatment of obesity. The latest edition, semaglutide, published impressive weight loss results and we are just beginning. There is a rich pipeline of future anti-obesity medications (AOM) that will give provides excellent options for both the treatment of obesity and of the obesity-related diseases. This session will start with reviewing some of the common pathophysiologic pathways that current and future AOM’s target then discuss emerging and future prospects of pharmacotherapy for the treatment of obesity.